Nifedipine: Complete Drug Monograph

Pharmacokinetic Profile

Half-Life

~2 h (elimination); apparent ~7 h (ER coat-core)

Metabolism

Hepatic (CYP3A4)

Protein Binding

92–98%

Bioavailability

45–75% (IR); ~86% relative (ER)

Volume of Distribution

0.62–0.77 L/kg

Clinical Information

Drug Class

Dihydropyridine CCB

Available Doses

IR: 10 mg cap; ER: 30, 60, 90 mg tab

Route

Oral

Renal Adjustment

Not required

Hepatic Adjustment

Use with caution; reduced clearance

Pregnancy

Used clinically (ACOG-endorsed for urgent BP control)

Lactation

Compatible; minimal infant exposure

Schedule

Prescription only (not scheduled)

Generic Available

Yes

Indications

Indication	Approved Population	Therapy Type	Status
Hypertension	Adults	Monotherapy or combination	FDA Approved
Chronic stable angina	Adults	Monotherapy or adjunctive with beta-blockers/nitrates	FDA Approved
Vasospastic angina (Prinzmetal)	Adults	Monotherapy	FDA Approved

Nifedipine is a well-established cardiovascular agent with three FDA-approved indications centered on its potent peripheral arterial vasodilation. For hypertension, extended-release formulations are preferred as first-line or add-on therapy. In chronic stable angina, nifedipine reduces afterload and myocardial oxygen demand; combination with a beta-blocker helps mitigate reflex tachycardia. In vasospastic angina, nifedipine directly inhibits coronary artery spasm, improving myocardial oxygen delivery.

Off-Label Uses

Raynaud phenomenon — first-line pharmacotherapy; reduces frequency and severity of attacks (Evidence: High)

Acute hypertension in pregnancy / postpartum — ACOG-endorsed for urgent BP control when IV access is unavailable; IR 10 mg orally, may repeat with 20 mg in 20 minutes (Evidence: High)

Tocolysis (preterm labor) — used as a short-term tocolytic; comparable efficacy to beta-agonists with fewer maternal side effects (Evidence: Moderate)

High-altitude pulmonary edema (HAPE) — used for both prevention and treatment; ER formulation preferred (Evidence: Moderate)

Chronic anal fissure — topical or oral; relaxes internal anal sphincter and promotes fissure healing (Evidence: Moderate)

Achalasia — reduces lower esophageal sphincter pressure; used when patients decline or await definitive therapy (Evidence: Low)

Distal ureteric calculi — medical expulsive therapy to facilitate stone passage (Evidence: Low)

Dose

Dosing

Adult Dosing by Clinical Scenario

Clinical Scenario	Starting Dose	Maintenance Dose	Maximum Dose	Notes
Hypertension — initial monotherapy	30 mg ER once daily	30–60 mg ER once daily	120 mg/day	Titrate over 7–14 days; preferred over IR Adalat CC: take on empty stomach
Hypertension — add-on to existing regimen	30 mg ER once daily	60–90 mg ER once daily	120 mg/day	May combine with ACE-I, ARB, or thiazide Monitor for additive hypotension
Chronic stable angina — ongoing prophylaxis	30–60 mg ER once daily	60–90 mg ER once daily	120 mg/day	Consider concurrent beta-blocker to offset reflex tachycardia Swallow ER tablets whole; do not crush
Vasospastic angina (Prinzmetal)	30 mg ER once daily	60–90 mg ER once daily	120 mg/day	Effective even with coexisting fixed coronary obstruction
Chronic stable angina — IR capsule regimen	10 mg TID	10–20 mg TID	180 mg/day	IR formulation; higher side-effect burden vs ER Use same total daily dose when converting IR to ER
Acute hypertension in pregnancy (off-label)	10 mg IR once	Repeat 20 mg IR in 20 min if needed	50 mg total in acute episode	ACOG-endorsed; avoid sublingual route Monitor maternal heart rate; higher reflex tachycardia than labetalol
Raynaud phenomenon (off-label)	30 mg ER once daily	30–60 mg ER once daily	120 mg/day	First-line pharmacotherapy; titrate per symptom response

Special Population Dosing

Population	Starting Dose	Maintenance Dose	Maximum Dose	Notes
Hepatic impairment	30 mg ER once daily	Lowest effective dose	Individualize	Increased bioavailability and prolonged half-life in cirrhosis; monitor closely
Elderly (≥65 years)	30 mg ER once daily	30–60 mg ER once daily	90 mg/day	Clearance reduced ~33%; avoid IR formulation (AGS Beers Criteria)
Pediatric hypertension (off-label)	0.2–0.5 mg/kg/dose	Per response	10 mg/dose	Not FDA-approved for pediatric use; AAFP guidelines

Clinical Pearl: IR-to-ER Conversion

When switching from immediate-release capsules to extended-release tablets, use the same total daily dose given once daily. For example, a patient on nifedipine IR 20 mg TID (60 mg/day) can convert to nifedipine ER 60 mg once daily. Note that two 30 mg Adalat CC tablets may substitute for one 60 mg tablet, but three 30 mg tablets should NOT substitute for one 90 mg tablet (different Cmax profile).

Pharmacology

Mechanism of Action

Nifedipine selectively blocks L-type voltage-gated calcium channels in vascular smooth muscle, reducing transmembrane calcium influx required for muscle contraction. This results in potent peripheral arterial vasodilation and decreased systemic vascular resistance, lowering blood pressure. In the coronary vasculature, nifedipine directly relaxes both large epicardial arteries and coronary arterioles, relieving vasospasm and enhancing myocardial oxygen delivery. Unlike non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, nifedipine has minimal effects on sinoatrial or atrioventricular nodal conduction at therapeutic doses. The reduction in cardiac afterload decreases myocardial oxygen consumption, which is the principal mechanism behind its efficacy in chronic stable angina. A modest reflex increase in heart rate and cardiac index typically accompanies the vasodilation, which can be attenuated by concurrent beta-blocker use.

ADME Profile

Parameter	Value	Clinical Implication
Absorption	Near-complete oral absorption; Tmax ~0.5–2 h (IR), ~6 h plateau (ER); bioavailability 45–75% (IR) due to first-pass effect; ER ~86% relative to IR	Significant first-pass hepatic metabolism limits systemic exposure with IR. Food slightly slows early absorption of ER but does not change total exposure. Short bowel syndrome may reduce ER absorption.
Distribution	Vd 0.62–0.77 L/kg; protein binding 92–98% (primarily albumin and alpha-1-acid glycoprotein)	Protein binding is markedly reduced in hepatic cirrhosis and renal impairment, potentially increasing free drug concentration and pharmacologic effect. Hemodialysis is ineffective due to high protein binding.
Metabolism	Extensive hepatic metabolism via CYP3A4 to inactive water-soluble metabolites	Susceptible to CYP3A4 drug interactions. Hepatic impairment prolongs half-life and raises bioavailability, necessitating dose caution. Grapefruit juice doubles exposure by inhibiting intestinal CYP3A4.
Elimination	60–80% renal (inactive metabolites); <0.1% unchanged in urine; remainder via biliary excretion in feces; elimination t½ ~2 h (drug molecule; IR capsule and GITS); apparent t½ ~7 h (coat-core ER formulations)	Renal impairment has minimal impact on pharmacokinetics; no dose adjustment required. Elderly show 33% reduction in clearance (IV data), warranting conservative dosing. ER formulations provide 24-hour duration of action despite the short intrinsic drug half-life.

Side Effects

≥10% Very Common

Adverse Effect	Incidence	Clinical Note
Dizziness / lightheadedness	27% (vs 15% placebo)	More frequent with IR formulations; usually resolves with continued therapy; advise caution with position changes
Flushing / heat sensation	25% (vs 8% placebo)	Direct consequence of vasodilation; typically transient; less pronounced with ER preparations
Headache	23% (vs 20% placebo)	Vasodilatory mechanism; onset usually within first week; often self-limiting; analgesics may be used short-term
Peripheral edema	10–30% (dose-dependent; ER formulation)	Localized arteriolar vasodilation, not fluid overload; dose-related (10% at 30 mg, ~30% at 180 mg); concurrent ACE-I/ARB may reduce
Weakness / fatigue	12% (vs 10% placebo)	Usually mild; may overlap with underlying disease burden
Nausea / heartburn	11% (vs 8% placebo)	GI smooth muscle relaxation may contribute; dose-related; taking with food may help with IR

1–10% Common

Adverse Effect	Incidence	Clinical Note
Muscle cramps / tremor	8% (vs 3% placebo)	May respond to magnesium supplementation if deficient
Palpitations	7% (vs 5% placebo)	Reflex sympathetic activation; typically reduces with ER formulations or concurrent beta-blocker
Nervousness / mood changes	7% (vs 4% placebo)	More common with IR; rarely requires discontinuation
Dyspnea / cough	6% (vs 3% placebo)	Not ACE-I class cough; evaluate for alternative causes including concurrent heart failure
Constipation	~3%	Less prominent than with verapamil; dietary measures usually sufficient
Gingival hyperplasia	~2%	Related to calcium-mediated fibroblast changes; risk increased with poor oral hygiene and concurrent phenytoin or cyclosporine
Leg cramps	<3%	Higher than placebo; only ER-specific adverse event exceeding placebo aside from edema and headache

Serious Serious (Regardless of Frequency)

Adverse Effect	Estimated Frequency	Typical Onset	Required Action
Myocardial infarction	~4% (uncontrolled angina cohort)	Days to weeks after initiation or dose increase	Discontinue; cardiology evaluation; avoid IR nifedipine post-MI
Severe hypotension	~5% (1 in 20, CHF subgroup)	Initial titration or dose escalation	Reduce dose or discontinue; IV fluids and vasopressors if symptomatic; more likely with concomitant beta-blocker or fentanyl anesthesia
Heart failure / pulmonary edema	~2%	Weeks to months; higher risk in aortic stenosis	Discontinue; standard heart failure management; avoid in severe aortic stenosis
Ventricular arrhythmias / conduction disturbances	<0.5%	Variable	ECG monitoring; discontinue if hemodynamically significant; cardiology consult
Syncope	~0.4% (1 in 250)	First days of therapy or dose increase	Evaluate for excessive hypotension; dose reduction or discontinuation
GI obstruction (ER tablet shell)	Rare	Variable; any time during therapy	Surgical evaluation if symptomatic; higher risk with GI strictures, bypasses, or hypomotility disorders
Stevens-Johnson syndrome / toxic epidermal necrolysis	Very rare	Days to weeks	Immediate discontinuation; dermatology consult; supportive care
Allergic hepatitis	Rare	1–2 months after starting therapy	Discontinue; LFTs normalize within 3–8 weeks; do not rechallenge

Discontinuation Discontinuation Rates

Extended-Release (ER) Studies

~5–10%

Top reasons: Peripheral edema, headache, dizziness

Immediate-Release (IR) Studies

Higher than ER (OR 1.7 vs active controls)

Top reasons: Flushing, headache, dizziness, palpitations

Reason for Discontinuation	Incidence	Context
Peripheral edema	Most common (ER)	Dose-dependent; higher at 90–120 mg/day; often the limiting factor for up-titration
Headache	Common	More frequent with IR; usually self-limiting but severe in some patients
Symptomatic hypotension	Less common	Higher risk with concomitant antihypertensives; warrants dose reduction before discontinuation
Worsening angina	Rare	Reported primarily with IR monotherapy in severe CAD; often necessitates agent switch

Managing Peripheral Edema

Nifedipine-induced edema is a local vasodilatory phenomenon affecting dependent arterioles, not a sign of fluid overload or heart failure. Adding an ACE inhibitor or ARB often alleviates the edema by reducing postcapillary venous pressure. Diuretics are less effective because the mechanism is precapillary vasodilation rather than sodium retention. If edema persists despite combination therapy, dose reduction or switch to a different antihypertensive class may be necessary. Always distinguish this from worsening heart failure in patients with reduced ejection fraction.

Int

Drug Interactions

Nifedipine undergoes extensive hepatic metabolism via CYP3A4, making it susceptible to interactions with both inhibitors and inducers of this enzyme. It is also a substrate and weak inhibitor of P-glycoprotein (P-gp). Most clinically significant interactions arise from altered nifedipine plasma concentrations or additive hemodynamic effects.

Major Rifampin

MechanismPotent CYP3A4 induction

EffectReduces nifedipine AUC by up to 70%; near-complete therapeutic failure

ManagementContraindicated per Adalat CC label; use alternative antihypertensive or alternative antimicrobial

FDA PI

Major Phenytoin / Carbamazepine

MechanismCYP3A4 induction

EffectPhenytoin reduces nifedipine exposure by ~70%; carbamazepine has similar effect

ManagementAvoid combination or use alternative CCB; if unavoidable, monitor BP closely and increase nifedipine dose as needed

FDA PI

Major Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin)

MechanismCYP3A4 inhibition reduces first-pass and systemic metabolism

EffectSignificantly increased nifedipine exposure; risk of hypotension, excessive vasodilation

ManagementStart at lowest nifedipine dose; monitor BP and symptoms closely; consider alternative agent or azithromycin (non-CYP3A4 inhibitor) for macrolide need

FDA PI

Major Grapefruit Juice

MechanismInhibition of intestinal CYP3A4

EffectUp to 2-fold increase in both AUC and Cmax

ManagementAvoid grapefruit and grapefruit juice entirely during nifedipine therapy

FDA PI

Moderate Beta-Blockers

MechanismAdditive hemodynamic effects (vasodilation + negative inotropy/chronotropy)

EffectGenerally well tolerated and therapeutically beneficial; rare cases of CHF, severe hypotension, or exacerbation of angina

ManagementMonitor BP; combination often used intentionally for angina and HTN; special caution in LV dysfunction or aortic stenosis

FDA PI

Moderate Digoxin

MechanismPossible P-gp inhibition and reduced renal clearance

EffectIsolated reports of elevated serum digoxin levels; risk of digitalis toxicity

ManagementMonitor digoxin levels at initiation, dose changes, and discontinuation of nifedipine

FDA PI

Moderate Cimetidine

MechanismCYP3A4 inhibition (moderate)

Effect~80% increase in peak nifedipine levels and ~74% increase in AUC

ManagementInitiate nifedipine cautiously if patient is on cimetidine; ranitidine has minimal effect and may be preferred

FDA PI

Moderate St. John’s Wort

MechanismCYP3A4 induction via hyperforin-mediated PXR activation

EffectSignificantly increased nifedipine clearance; reduced therapeutic efficacy

ManagementAvoid concurrent use; counsel patients about OTC herbal interactions

FDA PI

Minor Tacrolimus

MechanismCYP3A4 competition; nifedipine may reduce tacrolimus clearance

EffectElevated tacrolimus trough levels, particularly in CYP3A5 non-expressors

ManagementMonitor tacrolimus levels closely in transplant recipients; adjust dose as needed

Lexicomp

Minor Warfarin

MechanismUnknown; possibly protein binding displacement

EffectRare reports of increased prothrombin time

ManagementMonitor INR more frequently when initiating or changing nifedipine dose

FDA PI

Mon

Monitoring

Blood Pressure Baseline, each dose titration, then regularly
Routine Close monitoring during initial titration and dose changes. Seated and standing BP recommended to detect orthostatic component, particularly in elderly patients.
Heart Rate Baseline, each dose titration
Routine Assess for reflex tachycardia, especially with IR formulations or in patients not on concurrent beta-blocker therapy.
Peripheral Edema Each visit
Routine Dose-dependent; distinguish from heart failure in at-risk patients. Document severity and weight changes. Consider adding ACE-I/ARB before discontinuing nifedipine.
Liver Function Tests If symptoms arise
Trigger-based Rare transient elevations in ALP, LDH, SGOT, SGPT reported. Check LFTs if patient develops jaundice, pruritus, or unexplained malaise. Allergic hepatitis is rare but requires discontinuation.
Angina Symptoms Each visit (angina patients)
Routine Monitor for paradoxical worsening of angina frequency, duration, or severity, especially during initial therapy in patients with severe obstructive CAD.
Digoxin Levels At initiation and dose changes
Trigger-based Only in patients on concurrent digoxin. Isolated reports of elevated levels; monitor for signs of digitalis toxicity (nausea, visual changes, bradycardia).
Tacrolimus Levels At initiation and dose changes
Trigger-based In transplant recipients on tacrolimus; nifedipine can elevate trough levels, particularly in CYP3A5 non-expressors. Adjust tacrolimus dose accordingly.

Contraindications & Cautions

Absolute Contraindications

Known hypersensitivity to nifedipine or any formulation component
Concurrent strong CYP3A4 inducers (e.g., rifampin) — per Adalat CC label; near-complete loss of therapeutic effect
ST-elevation myocardial infarction (STEMI) — immediate-release nifedipine is associated with increased mortality in the acute MI setting

Relative Contraindications (Specialist Input Recommended)

Severe aortic stenosis — afterload reduction in fixed-outflow obstruction may cause hemodynamic collapse
Unstable angina / NSTEMI without concurrent beta-blocker — reflex tachycardia increases myocardial oxygen demand; may worsen ischemia
Cardiogenic shock — further reduction in cardiac contractility and vascular tone
Moderate to severe hepatic impairment — markedly increased bioavailability and prolonged half-life; requires close specialist supervision
Severe hypotension (SBP <90 mmHg) — vasodilation may worsen end-organ perfusion

Use with Caution

Heart failure with reduced ejection fraction — may worsen LV dysfunction; differentiate drug-induced peripheral edema from decompensation
Elderly patients — reduced clearance (~33%); avoid IR formulation per AGS Beers Criteria due to hypotension and ischemia risk
Patients with GI anatomical abnormalities (strictures, prior GI surgery, diverticulosis) — ER tablet shells may cause obstruction or ulceration
Concurrent high-dose fentanyl anesthesia — severe hypotension reported, especially with concurrent beta-blocker; allow at least 36 hours washout before planned surgery

FDA Class-Wide Regulatory Warning Short-Acting Nifedipine and Cardiovascular Mortality

Immediate-release nifedipine, particularly at moderate to high doses (60–80 mg/day), has been associated with a dose-dependent increase in all-cause mortality in patients with coronary artery disease, based on meta-analyses of secondary prevention trials (Furberg et al., Circulation 1995). The FDA has stated that immediate-release nifedipine should not be used for hypertension or for rapid blood pressure reduction in urgent or emergent settings. Extended-release formulations do not carry the same safety concern and have demonstrated favorable cardiovascular outcomes in large-scale trials (ACTION). Clinicians should avoid prescribing IR nifedipine for any indication when an ER alternative is available, except for specific short-term clinical scenarios (e.g., acute BP control in pregnancy under supervision).

Patient Counselling

Purpose of Therapy

Nifedipine is prescribed to lower blood pressure and prevent chest pain episodes. By relaxing blood vessels, it reduces the heart’s workload and improves blood and oxygen supply to the heart muscle. Controlling blood pressure reduces the long-term risk of stroke, heart attack, and kidney damage. For patients with angina, nifedipine helps prevent chest pain but does not stop an acute attack once it begins — short-acting nitroglycerin should be used for breakthrough episodes.

How to Take

Extended-release tablets must be swallowed whole and never crushed, chewed, or divided. Some formulations (such as Adalat CC) should be taken on an empty stomach, while others can be taken with or without food — patients should follow the specific instructions on their prescription label. If a dose is missed, take it as soon as remembered, unless it is nearly time for the next dose; never take two doses at once. An empty tablet shell may be visible in the stool — this is normal and means the medication has been released.

Swelling of Feet & Ankles

Tell patient Ankle swelling is a common and expected effect of nifedipine caused by localized blood vessel dilation, not heart failure. It is more likely at higher doses. Elevating the legs and wearing compression stockings may help. Do not stop the medication without consulting your prescriber, as the swelling can often be managed by adding another medication or adjusting the dose.

Call prescriber If swelling is severe, rapidly worsening, affects the face or hands, or is accompanied by shortness of breath, chest pain, or sudden weight gain (may indicate fluid overload rather than drug effect).

Dizziness & Lightheadedness

Tell patient Dizziness is common, particularly in the first days of treatment or after a dose increase. Rise slowly from sitting or lying positions. Avoid driving or operating machinery until you know how nifedipine affects you. This side effect usually improves within the first week or two.

Call prescriber If dizziness is severe, accompanied by fainting, or does not improve after the first two weeks of therapy.

Headache & Flushing

Tell patient Headache and facial flushing occur because the medication opens blood vessels. These effects are usually most noticeable during the first few days and tend to improve with continued use. Over-the-counter pain relief such as paracetamol can be used for headache.

Call prescriber If headache is severe, persistent beyond two weeks, or accompanied by visual disturbances.

Grapefruit Avoidance

Tell patient Do not eat grapefruit or drink grapefruit juice while taking nifedipine. Grapefruit can double the amount of nifedipine in your blood, increasing the risk of side effects such as low blood pressure and severe dizziness.

Call prescriber If you have consumed grapefruit products and experience excessive dizziness, flushing, or feel faint.

Do Not Stop Abruptly

Tell patient Do not stop taking nifedipine suddenly without medical advice. Abrupt discontinuation can lead to a rebound increase in blood pressure or worsening chest pain. If your prescriber decides to stop nifedipine, the dose should be reduced gradually.

Call prescriber If you accidentally run out of medication or miss several doses; seek guidance on restarting safely.

Dental Care

Tell patient Nifedipine can occasionally cause gum overgrowth (gingival hyperplasia). Maintaining thorough brushing, flossing, and regular dental check-ups helps reduce this risk. Inform your dentist that you are taking nifedipine.

Call prescriber If you notice persistent gum swelling, tenderness, or bleeding that does not respond to improved oral hygiene.

Ref

Sources

Regulatory (PI / SmPC)

Procardia XL (nifedipine) Extended Release Tablets. Full Prescribing Information. Pfizer Inc. Revised May 2014. labeling.pfizer.com Primary FDA-approved label for the extended-release GITS formulation; source of indications, dosing, adverse effects, and PK data for Procardia XL.
Adalat CC (nifedipine) Tablets. Full Prescribing Information. Bayer HealthCare. accessdata.fda.gov FDA label for the Adalat CC extended-release coat-core formulation; includes the rifampin contraindication and specific PK data for this formulation.
Procardia (nifedipine) Capsules. Full Prescribing Information. Pfizer Inc. accessdata.fda.gov FDA label for the immediate-release capsule formulation; source of IR-specific adverse effect incidence data from controlled clinical trials.

Key Clinical Trials

Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial). Lancet. 2004;364(9437):849-857. doi:10.1016/S0140-6736(04)16980-8 Landmark RCT of 7,665 patients demonstrating that long-acting nifedipine GITS was safe and reduced the need for coronary interventions in stable angina.
Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92(5):1326-1331. doi:10.1161/01.CIR.92.5.1326 Meta-analysis of 16 secondary prevention trials revealing dose-dependent mortality increase with short-acting nifedipine; foundational evidence for the safety advisory against IR nifedipine.
Sanusi AA, Leach J, Boggess K, et al. Pregnancy outcomes of nifedipine compared with labetalol for oral treatment of mild chronic hypertension. Obstet Gynecol. 2024;144(1):126-134. doi:10.1097/AOG.0000000000005616 Recent comparative trial supporting nifedipine as a first-line option for chronic hypertension in pregnancy, with better BP control in Black patients.

Guidelines

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006 Current ACC/AHA hypertension guideline placing CCBs including nifedipine as first-line agents, particularly for Black patients and older adults.
ACOG Practice Bulletin No. 222. Gestational hypertension and preeclampsia. Obstet Gynecol. 2020;135(6):e237-e260. doi:10.1097/AOG.0000000000003891 ACOG guidance endorsing oral nifedipine as an acceptable first-line agent for urgent blood pressure control in pregnancy.
American Geriatrics Society 2023 Updated Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 Includes immediate-release nifedipine on the potentially inappropriate medications list for older adults due to hypotension and ischemia risk.

Mechanistic / Basic Science

Godfraind T. Discovery and development of calcium channel blockers. Front Pharmacol. 2017;8:286. doi:10.3389/fphar.2017.00286 Comprehensive review of calcium channel blocker pharmacology, including nifedipine’s selectivity for L-type channels and vascular smooth muscle.
Nayler WG, Gu XH. The unique binding properties of nifedipine: an update. J Cardiovasc Pharmacol. 1991;17(Suppl 1):S1-S6. Describes the receptor binding pharmacology underlying nifedipine’s vascular selectivity and dihydropyridine class characteristics.

Pharmacokinetics / Special Populations

Khan KM, Patel JB, Patel P. Nifedipine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Updated July 6, 2025. ncbi.nlm.nih.gov Comprehensive overview including PK data across special populations (elderly, hepatic impairment, renal impairment, pregnancy, pediatrics), drug interactions, and off-label uses.
Krecic-Shepard ME, Barnas CR, Slimko J, et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000;40(3):219-230. doi:10.1177/00912700022008883 Supports understanding of CYP3A4-mediated CCB metabolism differences by sex and age, applicable to nifedipine dosing considerations.